FDA clears Zyga's sacroiliac joint fusion system
This article was originally published in Clinica
SImmetry, a minimally-invasive sacroiliac joint fusion system developed by Zyga Technology, has received 510(k) clearance from the US FDA. Dysfunction of the sacroiliac joint in the pelvis is thought to be responsible for around 30% of cases of low back pain. Eden Prairie, Minnesota-based Zyga’s system is intended to treat conditions including degenerative sacroiliitis and sacroiliac joint disruptions, and consists of a range of bone screws and associated instruments that are designed to transfix the sacrum and ilium and allow bony fusion. Other options for sacroiliac joint dysfunction include periodic injections, or open surgery to fuse the joint, which can lead to complications and poor outcomes.